Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 42 entries
Sorted by: Best Match Show Resources per page
DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Svanvik T, Strömberg U, Holmberg E, Marcickiewicz J, Sundfeldt K.
PMID: 30636711
Int J Gynecol Cancer. 2019 Feb;29(2):305-311. doi: 10.1136/ijgc-2018-000082. Epub 2019 Jan 13.

OBJECTIVES: To assess the effects on relative survival of established and new prognostic factors in stage I-III grade 1-3 endometrioid endometrial carcinoma and in the subgroup of stage I grade 1-2.METHODS: This was a population-based, retrospective study including all...

Cite
Svanvik T, Strömberg U, Holmberg E, et al. DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III. Int J Gynecol Cancer. 2019;29(2):305-311doi: 10.1136/ijgc-2018-000082.
Svanvik, T., Strömberg, U., Holmberg, E., Marcickiewicz, J., & Sundfeldt, K. (2019). DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 29(2), 305-311. https://doi.org/10.1136/ijgc-2018-000082
Svanvik, Teresia, et al. "DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 29,2 (2019): 305-311. doi: https://doi.org/10.1136/ijgc-2018-000082
Svanvik T, Strömberg U, Holmberg E, Marcickiewicz J, Sundfeldt K. DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III. Int J Gynecol Cancer. 2019 Feb;29(2):305-311. doi: 10.1136/ijgc-2018-000082. Epub 2019 Jan 13. PMID: 30636711.
Copy Download .nbib Format: NLM
Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics.

Clinical chemistry and laboratory medicine

Lycke M, Ulfenborg B, Malchau Lauesgaard J, Kristjansdottir B, Sundfeldt K.
PMID: 34388324
Clin Chem Lab Med. 2021 Aug 13;59(12):1954-1962. doi: 10.1515/cclm-2021-0510. Print 2021 Nov 25.

OBJECTIVES: To evaluate the impact of different biologic, histopathologic and lifestyle factors on serum levels of human epididymis protein 4 (HE4) and Cancer antigen 125 (CA125) in the diagnostic work up of women with an ovarian cyst or pelvic...

Cite
Lycke M, Ulfenborg B, Malchau Lauesgaard J, et al. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clin Chem Lab Med. 2021;59(12):1954-1962doi: 10.1515/cclm-2021-0510.
Lycke, M., Ulfenborg, B., Malchau Lauesgaard, J., Kristjansdottir, B., & Sundfeldt, K. (2021). Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clinical chemistry and laboratory medicine, 59(12), 1954-1962. https://doi.org/10.1515/cclm-2021-0510
Lycke, Maria, et al. "Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics." Clinical chemistry and laboratory medicine vol. 59,12 (2021): 1954-1962. doi: https://doi.org/10.1515/cclm-2021-0510
Lycke M, Ulfenborg B, Malchau Lauesgaard J, Kristjansdottir B, Sundfeldt K. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clin Chem Lab Med. 2021 Aug 13;59(12):1954-1962. doi: 10.1515/cclm-2021-0510. Print 2021 Nov 25. PMID: 34388324.
Copy Download .nbib Format: NLM
Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.

Proteomes

Mukherjee S, Sundfeldt K, Borrebaeck CAK, Jakobsson ME.
PMID: 34070600
Proteomes. 2021 May 25;9(2). doi: 10.3390/proteomes9020025.

Despite recent technological advancements allowing the characterization of cancers at a molecular level along with biomarkers for cancer diagnosis, the management of ovarian cancers (OC) remains challenging. Proteins assume functions encoded by the genome and the complete set of...

Cite
Mukherjee S, Sundfeldt K, Borrebaeck CAK, et al. Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. Proteomes. 2021;9(2)doi: 10.3390/proteomes9020025.
Mukherjee, S., Sundfeldt, K., Borrebaeck, C. A. K., & Jakobsson, M. E. (2021). Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. Proteomes, 9(2), . https://doi.org/10.3390/proteomes9020025
Mukherjee, Shuvolina, et al. "Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers." Proteomes vol. 9,2 (2021). doi: https://doi.org/10.3390/proteomes9020025
Mukherjee S, Sundfeldt K, Borrebaeck CAK, Jakobsson ME. Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. Proteomes. 2021 May 25;9(2). doi: 10.3390/proteomes9020025. PMID: 34070600; PMCID: PMC8163166.
Copy Download .nbib Format: NLM
Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay.

Glycobiology

Mateoiu C, Vitiazeva V, Kristjansdottir B, Weijdegård B, Örnros J, Gallini R, Kamali-Moghaddam M, Sundfeldt K, Karlsson NG.
PMID: 34459484
Glycobiology. 2021 Dec 18;31(11):1464-1471. doi: 10.1093/glycob/cwab090.

MUC5AC has been indicated to be a marker for mucinous ovarian cancer (OC). We investigated the use of in situ proximity ligation assay (PLA) for blood group ABH expressing MUC5AC to differentiate between serous and mucinous OC, to validate...

Cite
Mateoiu C, Vitiazeva V, Kristjansdottir B, et al. Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay. Glycobiology. 2021;31(11):1464-1471doi: 10.1093/glycob/cwab090.
Mateoiu, C., Vitiazeva, V., Kristjansdottir, B., Weijdegård, B., Örnros, J., Gallini, R., Kamali-Moghaddam, M., Sundfeldt, K., & Karlsson, N. G. (2021). Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay. Glycobiology, 31(11), 1464-1471. https://doi.org/10.1093/glycob/cwab090
Mateoiu, Constantina, et al. "Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay." Glycobiology vol. 31,11 (2021): 1464-1471. doi: https://doi.org/10.1093/glycob/cwab090
Mateoiu C, Vitiazeva V, Kristjansdottir B, Weijdegård B, Örnros J, Gallini R, Kamali-Moghaddam M, Sundfeldt K, Karlsson NG. Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay. Glycobiology. 2021 Dec 18;31(11):1464-1471. doi: 10.1093/glycob/cwab090. PMID: 34459484; PMCID: PMC8684467.
Copy Download .nbib Format: NLM
Dental Care during COVID-19 Outbreak: A Web-Based Survey.

European journal of dentistry

Faccini M, Ferruzzi F, Mori AA, Santin GC, Oliveira RC, Oliveira RCG, Queiroz PM, Salmeron S, Pini NIP, Sundfeld D, Freitas KMS.
PMID: 32882738
Eur J Dent. 2020 Dec;14:S14-S19. doi: 10.1055/s-0040-1715990. Epub 2020 Sep 03.

OBJECTIVE:  This survey aimed to assess the effects of coronavirus disease 2019 (COVID-19) on elective and urgency/emergency dental care and dentists concerned.MATERIALS AND METHODS:  A web-based survey was performed using Google forms questionnaire sent to dentists in Brazil. Questions...

Cite
Faccini M, Ferruzzi F, Mori AA, et al. Dental Care during COVID-19 Outbreak: A Web-Based Survey. Eur J Dent. 2020;14:S14-S19doi: 10.1055/s-0040-1715990.
Faccini, M., Ferruzzi, F., Mori, A. A., Santin, G. C., Oliveira, R. C., Oliveira, R. C. G., Queiroz, P. M., Salmeron, S., Pini, N. I. P., Sundfeld, D., & Freitas, K. M. S. (2020). Dental Care during COVID-19 Outbreak: A Web-Based Survey. European journal of dentistry, 14S14-S19. https://doi.org/10.1055/s-0040-1715990
Faccini, Melissa, et al. "Dental Care during COVID-19 Outbreak: A Web-Based Survey." European journal of dentistry vol. 14 (2020): S14-S19. doi: https://doi.org/10.1055/s-0040-1715990
Faccini M, Ferruzzi F, Mori AA, Santin GC, Oliveira RC, Oliveira RCG, Queiroz PM, Salmeron S, Pini NIP, Sundfeld D, Freitas KMS. Dental Care during COVID-19 Outbreak: A Web-Based Survey. Eur J Dent. 2020 Dec;14:S14-S19. doi: 10.1055/s-0040-1715990. Epub 2020 Sep 03. PMID: 32882738; PMCID: PMC7775249.
Copy Download .nbib Format: NLM
Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers.

Journal of clinical medicine

Lycke M, Ulfenborg B, Kristjansdottir B, Sundfeldt K.
PMID: 31973047
J Clin Med. 2020 Jan 21;9(2). doi: 10.3390/jcm9020299.

Ovarian cancer is the most lethal gynecologic cancer. Pre-diagnostic testing lacks sensitivity and specificity, and surgery is often the only way to secure the diagnosis. Exploring new biomarkers is of great importance, but the rationale of combining validated well-established...

Cite
Lycke M, Ulfenborg B, Kristjansdottir B, et al. Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers. J Clin Med. 2020;9(2)doi: 10.3390/jcm9020299.
Lycke, M., Ulfenborg, B., Kristjansdottir, B., & Sundfeldt, K. (2020). Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers. Journal of clinical medicine, 9(2), . https://doi.org/10.3390/jcm9020299
Lycke, Maria, et al. "Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers." Journal of clinical medicine vol. 9,2 (2020). doi: https://doi.org/10.3390/jcm9020299
Lycke M, Ulfenborg B, Kristjansdottir B, Sundfeldt K. Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers. J Clin Med. 2020 Jan 21;9(2). doi: 10.3390/jcm9020299. PMID: 31973047; PMCID: PMC7073859.
Copy Download .nbib Format: NLM
Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors.

Molecular & cellular proteomics : MCP

Thomsson KA, Vitiazeva V, Mateoiu C, Jin C, Liu J, Holgersson J, Weijdegård B, Sundfeldt K, Karlsson NG.
PMID: 34555499
Mol Cell Proteomics. 2021;20:100150. doi: 10.1016/j.mcpro.2021.100150. Epub 2021 Sep 21.

Despite sulfated O-linked glycans being abundant on ovarian cancer (OC) glycoproteins, their regulation during cancer development and involvement in cancer pathogenesis remain unexplored. We characterized O-glycans carrying sulfation on galactose residues and compared their expression with defined sulfotransferases regulated...

Cite
Thomsson KA, Vitiazeva V, Mateoiu C, et al. Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors. Mol Cell Proteomics. 2021;20:100150doi: 10.1016/j.mcpro.2021.100150.
Thomsson, K. A., Vitiazeva, V., Mateoiu, C., Jin, C., Liu, J., Holgersson, J., Weijdegård, B., Sundfeldt, K., & Karlsson, N. G. (2021). Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors. Molecular & cellular proteomics : MCP, 20100150. https://doi.org/10.1016/j.mcpro.2021.100150
Thomsson, Kristina A, et al. "Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors." Molecular & cellular proteomics : MCP vol. 20 (2021): 100150. doi: https://doi.org/10.1016/j.mcpro.2021.100150
Thomsson KA, Vitiazeva V, Mateoiu C, Jin C, Liu J, Holgersson J, Weijdegård B, Sundfeldt K, Karlsson NG. Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors. Mol Cell Proteomics. 2021;20:100150. doi: 10.1016/j.mcpro.2021.100150. Epub 2021 Sep 21. PMID: 34555499; PMCID: PMC8527052.
Copy Download .nbib Format: NLM
Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer.

Frontiers in oncology

Weiland F, Lokman NA, Klingler-Hoffmann M, Jobling T, Stephens AN, Sundfeldt K, Hoffmann P, Oehler MK.
PMID: 33102207
Front Oncol. 2020 Sep 25;10:1767. doi: 10.3389/fonc.2020.01767. eCollection 2020.

Ovarian cancer is the most lethal gynecologic malignancy. Early detection would improve survival, but an effective diagnostic test does not exist. Novel biomarkers for early ovarian cancer diagnosis are therefore warranted. We performed intraoperative blood sampling from ovarian veins...

Cite
Weiland F, Lokman NA, Klingler-Hoffmann M, et al. Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer. Front Oncol. 2020;10:1767doi: 10.3389/fonc.2020.01767.
Weiland, F., Lokman, N. A., Klingler-Hoffmann, M., Jobling, T., Stephens, A. N., Sundfeldt, K., Hoffmann, P., & Oehler, M. K. (2020). Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer. Frontiers in oncology, 101767. https://doi.org/10.3389/fonc.2020.01767
Weiland, Florian, et al. "Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer." Frontiers in oncology vol. 10 (2020): 1767. doi: https://doi.org/10.3389/fonc.2020.01767
Weiland F, Lokman NA, Klingler-Hoffmann M, Jobling T, Stephens AN, Sundfeldt K, Hoffmann P, Oehler MK. Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer. Front Oncol. 2020 Sep 25;10:1767. doi: 10.3389/fonc.2020.01767. eCollection 2020. PMID: 33102207; PMCID: PMC7545354.
Copy Download .nbib Format: NLM
Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.

The Journal of pathology

Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SCY, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitze F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FKF, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PDP, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS.
PMID: 34897700
J Pathol. 2021 Dec 13; doi: 10.1002/path.5849. Epub 2021 Dec 13.

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response,...

Cite
Heinze K, Nazeran TM, Lee S, et al. Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2021;doi: 10.1002/path.5849.
Heinze, K., Nazeran, T. M., Lee, S., Krämer, P., Cairns, E. S., Chiu, D. S., Leung, S. C. Y., Kang, E. Y., Meagher, N. S., Kennedy, C. J., Boros, J., Kommoss, F., Vollert, H. W., Heitze, F., du Bois, A., Harter, P., Grube, M., Kraemer, B., Staebler, A., Kommoss, F. K. F., Heublein, S., Sinn, H. P., Singh, N., Laslavic, A., Elishaev, E., Olawaiye, A., Moysich, K., Modugno, F., Sharma, R., Brand, A. H., Harnett, P. R., DeFazio, A., Fortner, R. T., Lubinski, J., Lener, M., Tołoczko-Grabarek, A., Cybulski, C., Gronwald, H., Gronwald, J., Coulson, P., El-Bahrawy, M. A., Jones, M. E., Schoemaker, M. J., Swerdlow, A. J., Gorringe, K. L., Campbell, I., Cook, L., Gayther, S. A., Carney, M. E., Shvetsov, Y. B., Hernandez, B. Y., Wilkens, L. R., Goodman, M. T., Mateoiu, C., Linder, A., Sundfeldt, K., Kelemen, L. E., Gentry-Maharaj, A., Widschwendter, M., Menon, U., Bolton, K. L., Alsop, J., Shah, M., Jimenez-Linan, M., Pharoah, P. D. P., Brenton, J. D., Cushing-Haugen, K. L., Harris, H. R., Doherty, J. A., Gilks, B., Ghatage, P., Huntsman, D. G., Nelson, G. S., Tinker, A. V., Lee, C. H., Goode, E. L., Nelson, B. H., Ramus, S. J., Kommoss, S., Talhouk, A., Köbel, M., & Anglesio, M. S. (2021). Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. The Journal of pathology, . https://doi.org/10.1002/path.5849
Heinze, Karolin, et al. "Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas." The Journal of pathology vol. (2021). doi: https://doi.org/10.1002/path.5849
Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SCY, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitze F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FKF, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PDP, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS. Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2021 Dec 13; doi: 10.1002/path.5849. Epub 2021 Dec 13. PMID: 34897700.
Copy Download .nbib Format: NLM
Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer.

Cancers

Liljedahl L, Malmström J, Kristjansdottir B, Waldemarson S, Sundfeldt K.
PMID: 34830868
Cancers (Basel). 2021 Nov 15;13(22). doi: 10.3390/cancers13225713.

Epithelial ovarian cancer (OC) is a disease with high mortality due to vague early clinical symptoms. Benign ovarian cysts are common and accurate diagnosis remains a challenge because of the molecular heterogeneity of OC. We set out to investigate...

Cite
Liljedahl L, Malmström J, Kristjansdottir B, et al. Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer. Cancers (Basel). 2021;13(22)doi: 10.3390/cancers13225713.
Liljedahl, L., Malmström, J., Kristjansdottir, B., Waldemarson, S., & Sundfeldt, K. (2021). Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer. Cancers, 13(22), . https://doi.org/10.3390/cancers13225713
Liljedahl, Leena, et al. "Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer." Cancers vol. 13,22 (2021). doi: https://doi.org/10.3390/cancers13225713
Liljedahl L, Malmström J, Kristjansdottir B, Waldemarson S, Sundfeldt K. Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer. Cancers (Basel). 2021 Nov 15;13(22). doi: 10.3390/cancers13225713. PMID: 34830868; PMCID: PMC8616310.
Copy Download .nbib Format: NLM
Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors.

Molecular & cellular proteomics : MCP

Thomsson KA, Vitiazeva V, Mateoiu C, Jin C, Liu J, Holgersson J, Weijdegård B, Sundfeldt K, Karlsson NG.
PMID: 34555499
Mol Cell Proteomics. 2021 Sep 21;20:100150. doi: 10.1016/j.mcpro.2021.100150. Epub 2021 Sep 21.

Despite sulfated O-linked glycans being abundant on ovarian cancer (OC) glycoproteins, their regulation during cancer development and involvement in cancer pathogenesis remain unexplored. We characterized O-glycans carrying sulfation on galactose residues and compared their expression with defined sulfotransferases regulated...

Cite
Thomsson KA, Vitiazeva V, Mateoiu C, et al. Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors. Mol Cell Proteomics. 2021;20:100150doi: 10.1016/j.mcpro.2021.100150.
Thomsson, K. A., Vitiazeva, V., Mateoiu, C., Jin, C., Liu, J., Holgersson, J., Weijdegård, B., Sundfeldt, K., & Karlsson, N. G. (2021). Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors. Molecular & cellular proteomics : MCP, 20100150. https://doi.org/10.1016/j.mcpro.2021.100150
Thomsson, Kristina A, et al. "Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors." Molecular & cellular proteomics : MCP vol. 20 (2021): 100150. doi: https://doi.org/10.1016/j.mcpro.2021.100150
Thomsson KA, Vitiazeva V, Mateoiu C, Jin C, Liu J, Holgersson J, Weijdegård B, Sundfeldt K, Karlsson NG. Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors. Mol Cell Proteomics. 2021 Sep 21;20:100150. doi: 10.1016/j.mcpro.2021.100150. Epub 2021 Sep 21. PMID: 34555499; PMCID: PMC8527052.
Copy Download .nbib Format: NLM
Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry.

Frontiers in oncology

Engqvist H, Parris TZ, Kovács A, Rönnerman EW, Sundfeldt K, Karlsson P, Helou K.
PMID: 32133296
Front Oncol. 2020 Feb 18;10:162. doi: 10.3389/fonc.2020.00162. eCollection 2020.

Early-stage (I and II) ovarian carcinoma patients generally have good prognosis. Yet, some patients die earlier than expected. Thus, it is important to stratify early-stage patients into risk groups to identify those in need of more aggressive treatment regimens....

Cite
Engqvist H, Parris TZ, Kovács A, et al. Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry. Front Oncol. 2020;10:162doi: 10.3389/fonc.2020.00162.
Engqvist, H., Parris, T. Z., Kovács, A., Rönnerman, E. W., Sundfeldt, K., Karlsson, P., & Helou, K. (2020). Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry. Frontiers in oncology, 10162. https://doi.org/10.3389/fonc.2020.00162
Engqvist, Hanna, et al. "Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry." Frontiers in oncology vol. 10 (2020): 162. doi: https://doi.org/10.3389/fonc.2020.00162
Engqvist H, Parris TZ, Kovács A, Rönnerman EW, Sundfeldt K, Karlsson P, Helou K. Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry. Front Oncol. 2020 Feb 18;10:162. doi: 10.3389/fonc.2020.00162. eCollection 2020. PMID: 32133296; PMCID: PMC7040170.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 42 entries